All News

DDW 2023 study claims microscopic colitis (MC) pts had a 2fold higher risk of #RA. 11,293 MC pts matched 1:5 w/ population controls. With 8 yrs of F/U, RA was found in 1.1% of MC vs 0.6% controls (adj HR 1.92 (95% CI = 1.56-2.34). https://t.co/R5faYDoaAq https://t.co/qiaOMgOyLR

Links:

Dr. John Cush RheumNow ( View Tweet)
Stop RA trail: Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/gO9QKbAues https://t.co/gEpuBvDpj5

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/Og1vvbTRO9 https://t.co/WyqPH0lgkd

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKinib safety takeaways - avoid in older population 65 yo, malignancy, CV risk, VTE risk - appropriate in younger pts without VTE/CVD risk factors #RNL2023 @RheumNow https://t.co/mFvvqJ9Jbp https://t.co/A76tR2S1Rb

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/zncCw3jlK7 https://t.co/AHhDyxaumM

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV

Links:

Dr. John Cush RheumNow ( View Tweet)
How do you prevent RA in at-risk patient? Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷 Education follow-up! Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD #RNL2023

Dr. John Cush RheumNow ( View Tweet)

STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts @RheumNow #RNL2023 https://t.co/uZRqAxWyyo https://t.co/02qUN4Hhrc

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Audience RA Questions from RNL23 Audience Questions & Answers from RNL23 on Rheumatoid Arthritis https://t.co/vh1Tzstbwl https://t.co/IUXfAlzPoE

Links:

Dr. John Cush RheumNow ( View Tweet)
question-mark-1872634_640.jpg

ICYMI: What to do about pre-clinical RA?

d Robert Chao, MD

RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.

Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?

Read Article
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

National Population Insights (4.28.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/PYsTGnejOF https://t.co/AqOiiZm3uI

Links:

Dr. John Cush RheumNow ( View Tweet)
Giants,women,rheumatology

25 Great Women in Rheumatology

d Jack Cush, MD

This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

Read Article
Dr. Jeff Sparks talks sex differences and rheumatoid arthritis associated interstitial lung disease. https://t.co/asUrfXw2Y1 https://t.co/oLwi8BvquO

Links:

Dr. John Cush RheumNow ( View Tweet)
Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis Lancet Rheumatology has published a retrospective analysis showing patients receiving ICI for cancer have the same outcomes even when they have pre-existing RA. https://t.co/aFNZX5YaLD https://t.co/ZY9Ie8TOPc

Links:

Dr. John Cush RheumNow ( View Tweet)
Brigham review (2018-2022) of 47 CPPD pts: M=F, mean age 72 yrs 68% w/ acute CPP arthritis 40% w/ CPP inflammatory arthritis 62% w/ OA with CPPD. Compared to Gout, CPPD Significant unmet Rx need & lower RAPID3 (8.1 vs 12.1) https://t.co/cLNjGxi6qF https://t.co/76PoepxRjR

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us 4/25 as we conclude our Women in Rheumatology campaign by focusing on what's next. Our panelists will recap the challenges addressed this month and discuss a strategy to suppot women in rheumatology. https://t.co/DP4S2hf5Tz @uptoTate @KDAO2011 @gwenesta_melton https://t.co/rcglaZxqoF

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.